Livzon Pharmaceutical Group Inc.
000513
Rangering i aksjer
#4689
Livzon Pharmaceutical Group Inc., headquartered in Zhuhai, China, and... Livzon Pharmaceutical Group Inc., headquartered in Zhuhai, China, and established in 1985, is a biopharmaceutical enterprise operating across the entire spectrum of pharmaceutical activities, from research and development to manufacturing and commercialization. The company's operations encompass a diverse range of finished drug products, active pharmaceutical ingredients (APIs), and chemical intermediates, primarily serving the Chinese market while also engaging in international exports. Its pharmaceutical portfolio includes treatments such as Ilaprazole enteric coated tablets for duodenal ulcers and reflux esophagitis, Laprazole sodium injection for managing peptic ulcer bleeding, Leuprorelin Acetate Microspheres for injection, and Urofollitropin injection for anovulation and fertility support. Livzon also produces Perospirone Hydrochloride for schizophrenia, Anti-viral Granules targeting upper respiratory tract infections and influenza, and Shenqi Fuzheng Injection, which addresses general weakness, fatigue, spontaneous sweating, and vertigo, and provides supportive care for lung and stomach cancer patients. Beyond therapeutic drugs, Livzon Pharmaceutical Group develops and distributes a variety of diagnostic reagents. These include kits for detecting IgM/IgG antibodies to coronavirus, nucleic acid tests for human immunodeficiency virus type 1, antinuclear antibody test kits, interferon-gamma release assay kits, and rapid tests for mycoplasma pneumoniae IgM antibodies. The company's extensive offerings further extend to biochemical drugs, microbiological preparations, biologics, traditional Chinese medicine formulations, pharmaceutical raw materials, and antibiotics.
Aksjekurs
$3.90
Markedsverdi
$3.17B
Endring (1 dag)
-3.49%
Endring (1 år)
-25.88%
Land
CN
Handel Livzon Pharmaceutical Group Inc. (000513)
Kategori
Healthcare
Inntekter for Livzon Pharmaceutical Group Inc. (000513)
Inntekter i Jun 2026 TTM: $353.39M
Ifølge Livzon Pharmaceutical Group Inc. sine nyeste økonomiske rapporter er selskapets nåværende resultat $353.39M. I 2024 hadde selskapet et resultat på $384.45M, en økning sammenlignet med resultatet i 2023, som var $336.60M. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Livzon Pharmaceutical Group Inc. fra 2001 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $353.39M | -13.61% |
| 2025 | $409.07M | 6.40% |
| 2024 | $384.45M | 14.22% |
| 2023 | $336.60M | -0.37% |
| 2022 | $337.86M | -4.38% |
| 2021 | $353.32M | -7.28% |
| 2020 | $381.07M | 53.60% |
| 2019 | $248.09M | 20.46% |
| 2018 | $205.95M | -76.59% |
| 2017 | $879.92M | 507.84% |
| 2016 | $144.76M | 16.35% |
| 2015 | $124.42M | 18.19% |
| 2014 | $105.27M | 1.52% |
| 2013 | $103.69M | 15.39% |
| 2012 | $89.85M | 22.30% |
| 2011 | $73.47M | -9.13% |
| 2010 | $80.85M | -6.35% |
| 2009 | $86.33M | 457.58% |
| 2008 | $15.48M | -81.76% |
| 2007 | $84.91M | 200.91% |
| 2006 | $28.22M | 72.44% |
| 2005 | $16.36M | -12.46% |
| 2004 | $18.69M | -1.91% |
| 2003 | $19.06M | 40.37% |
| 2002 | $13.58M | 11.75% |
| 2001 | $12.15M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $3.62B | 923.75% |
DE
|
|
| $3.40B | 863.51% |
DE
|
|
| $1.72B | 387.73% |
JP
|
|
| $930.30M | 163.25% |
CH
|
|
| $1.69B | 378.97% |
IN
|
